Human Thrombomodulin/BDCA-3 APC-conjugated Antibody

Catalog #: FAB3947A Datasheet / COA / SDS

Catalog #	Availability	Size / Price	Qty
FAB3947A

Detection of Thrombomodulin/BDCA‑3 in Human PBMCs by Flow Cytometry.

1 Image

Product Details

Supplemental Products

Reviews

Summary Data Examples Preparation and Storage Reconstitution Calculator Background Product Datasheets Related Research Areas

Human Thrombomodulin/BDCA-3 APC-conjugated Antibody Summary

Species Reactivity

Human

Specificity

Detects human Thrombomodulin/BDCA-3 in ELISAs.

Source

Monoclonal Mouse IgG₁ Clone # 501733

Purification

Protein A or G purified from hybridoma culture supernatant

Immunogen

Mouse myeloma cell line NS0-derived recombinant human Thrombomodulin/BDCA-3
Ala19-Ser515
Accession # P07204(Val473)

Formulation

Supplied in a saline solution containing BSA and Sodium Azide.

Label

Allophycocyanin (Excitation= 620-650 nm, Emission= 660-670 nm)

Applications

Recommended Concentration

Sample

Flow Cytometry

10 µL/10⁶ cells

See below

Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.

Scientific Data

Flow Cytometry

View Larger

Detection of Thrombomodulin/BDCA‑3 in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) were stained with Mouse Anti-Human Thrombomodulin/BDCA-3 APC-conjugated Monoclonal Antibody (Catalog # FAB3947A) and Mouse Anti-Human HLA-DR Fluorescein-conjugated Monoclonal Antibody (Catalog # FAB4869F). Quadrant markers were set based on isotype control antibody staining. View our protocol for Staining Membrane-associated Proteins.

Reconstitution Calculator

Preparation and Storage

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store the unopened product at 2 - 8° C. Do not use past expiration date. Protect from light.

Background: Thrombomodulin/BDCA-3

Encoded by the THBD gene, Thrombomodulin is also known as Blood Dendritic Cell Antigen 3 (BDCA‑3) and designated CD141. The deduced amino acid (aa) sequence of human THBD predicts a signal peptide (aa 1‑18) and a mature chain (aa 19‑575) that consists of the following domains: a C‑type lectin domain (aa 31‑169), EGF‑like domains (aa 241‑281, aa 284‑324, aa 325‑363, aa 365‑405, aa 404‑440, and aa 441‑481), a transmembrane domain (aa 516 to 539), and a cytoplasmic region (aa 540‑575). The region used as an immunogen consists of aa 19‑515, corresponding to the extracellular portion of the type I transmembrane protein. Predominantly synthesized by vascular endothelial cells, THBD inhibits coagulation and fibrinolysis (1‑3). It functions as a cell surface receptor and an essential cofactor for active thrombin, which, in turn, activates Protein C and Thrombin‑activatable Fibrinolysis Inhibitor (TAFI), also known as Carboxypeptidase B2 (CPB2). Activated protein C (APC), facilitated by Protein S, degrades coagulation factors Va and VIIIa, which are required for thrombin activation. Activated CPB2 cleaves basic C‑terminal aa residues of its substrates, including fibrin, preventing the conversion of plasminogen to plasmin. In addition, THBD gene polymorphisms are associated with human disease and with THBD playing a role in thrombosis, stroke, arteriosclerosis, and cancer (4). For example, increased serum levels of THBD due to protease cleavage have been associated with smoking, cardiac surgery, atherosclerosis, liver cirrhosis, diabetes mellitus, cerebral and myocardial infarction, and multiple sclerosis (5).

References